HIPERFECT
LIVE

Serial Number

79055263

Owner

QIAGEN GMBH

Attorney

Victoria Friedman

Filing Date

Dec 20, 2007

Add to watchlist:

No watchlists yet
View on USPTO

HIPERFECT Trademark

Serial Number: 79055263 • Registration: 3754819

HIPERFECT is a trademark filed by QIAGEN GMBH on December 20, 2007. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

QIAGEN GMBH (211 trademarks)

HILDEN D-4010 , DE

Entity Type: 03

Trademark Details

Filing Date

December 20, 2007

Registration Date

March 2, 2010

Published for Opposition

December 15, 2009

Goods & Services

[ Scientific apparatuses, instruments and equipment and laboratory instruments and measuring apparatuses and instruments in particular for research, medical, diagnostic and analysis purposes, namely, disposable laboratory articles, namely, plastic vessels, sample storage vessels, reaction and collection vessels and plates, multi-well plates, tips, including filter tips and dispenser tips, pipette tips and tip boxes, tubes, microtubes and tubes for PCR and micro centrifuges and micro-injection, capillaries, curvettes, spin columns, cartridges and columns filed with chromatographic material for the separation, purification, and isolation of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material, in particular nucleic acids from biological or biochemical sample material, in particular for transfection, racks and holders for samples storage vessels, tubes, syringes and tips; sample presentation devices, mircroarrays, chips, MALDI-MS presentation devices; laboratory robots, robotic workstations and systems and laboratory incubators for diagnostic, clinical and research applications for the preparation, modification, isolation, crystallization, handling, amplification and manipulation of samples and for the transfecting, marking, separation, isolation, purification, reproduction and analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material, in particular nucleic acids from biological or biochemical sample material, laboratory apparatuses and equipment for dosage, dispensing, transferring, temperature equalizing, agitating, mixing, diluting, concentrating, transfecting and separating of liquids, MALDI- apparatuses, workstations for reading and handling multi-well plates for the analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material in particular nucleic acids from biological or biochemical sample material, in particular for nucleic acid amplification, in particular by polymerase chain reaction (PCR); laboratory equipment, namely, cyclers, thermocyclers, lysis apparatuses, disrupters, physico-chemical, bio-chemical, optical and electronic analysis apparatus and equipment, in particular photometers, spectrophotometers, optical scanners for detection of fluorescence and colorimetric signals; apparatuses for processing cells or liquids containing cells in particular electroporators, electrofusion apparatuses, transfection apparatuses, micro injectors and micro manipulators; vacuum chambers for chromatography, purification, separation and characterization of natural and synthetic biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material; centrifuges; vacuum systems for laboratory use, vacuum concentrators; centrifugal concentrators; rotors for laboratory centrifuges and vacuum concentrators, mixers; mechanical, electronical and automatical pipettes and dispensers for dispensing liquid for laboratory research and analysis purposes ]

[ Diagnostic preparations for medical and veterinary purposes; pharmaceutical and veterinary products, namely, nucleic acid sequences, chemical reagents and biochemical preparations for medical or veterinary purposes; nucleic acid sequences for diagnostic and/or pharmaceutical purposes; anionic, cationic and zwitterionic lipids and mixtures thereof for the introduction of molecules into cells for diagnostic and/or pharmaceutical purposes; medical or diagnostic transfection reagents for diagnostic and/or pharmaceutical purposes; kits comprising chemical reagents for medical and veterinary-diagnostic purposes, kits comprising biochemical preparations for medical and veterinary-diagnostic purposes and kits comprising biotechnological products, namely, transfection reagents, anionic, cationic and zwitterionic lipids and mixtures thereof for the introduction of molecules into cells, all of the foregoing for medical, veterinary and/or diagnostic purposes ]

Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, [ nucleic acids for laboratory and laboratory research use, enzymes, polymerases, chemical and biochemical reagents for staining and marking for laboratory and research use, chemical and biochemical reagents commonly known as probes for detecting and analyzing molecules in protein or nucleic acid arrays, ] transfection reagents for research purposes, anionic, cationic and zwitterionic lipids and mixtures thereof for introducing chemical, biochemical and biotechnological products into cells, [ chemical buffers used in analytical chemistry and biochemistry, aqueous and non-aqueous solutions of alcohols and/or salts, namely, solutions containing isopropanol, ethanol, methanol, propanol, butanol or PEG and solutions containing chaotropic salts, distilled water, column and membrane material comprising silicium dioxide for the isolation, purification or separation of chemical, biochemical and biotechnological products, none of the foregoing for medical or veterinary purposes; ] chemicals and biochemicals for industrial and scientific purposes, [ namely, reagents for research purposes for industrial and commercial use for sample preparation, purification, lysis, modification and manipulation of cells and tissues, ] namely, transfection chemical reagents for non-medical purposes, chemical reagents for non-medical purposes [ and aromatic solvents for industrial and commercial use for performing marking, separating, isolating, purification, amplification, and/or analysis methods of biopolymers, namely, nucleic acids, enzymes, proteins, macromolecules and biologically active substances for separation, modification, analysis, marking, amplification and purification of biological and chemical compounds, none of the foregoing for medical or veterinary purposes; kits comprising chemical preparations for scientific and chemicals for industrial purposes, ] kits comprising biochemicals for scientific or industrial purposes and kits comprising biotechnological products for scientific purposes, namely, biochemical catalysts, transfection chemical reagents for non-medical purposes, anionic, cationic and zwitterionic lipids and mixtures thereof for introducing chemical, biochemical and biotechnological products into cells, nucleic acids for laboratory use, oligonucleotides for scientific research, enzymes for scientific and research purposes, proteins for scientific research, chemical and biochemical reagents for staining and marking for non-medical purposes, chemical and biochemical reagents commonly known as probes for detecting and analysing molecules in protein or nucleic acid arrays and/or comprising chemical buffers for industrial and commercial use for sample preparation, purification, lysis, modification and manipulation of cells or tissue and for performing marking, separating, isolating, purification, amplification and/or analysis methods for biopolymers, namely, nucleic acids, enzymes, proteins, macromolecules, none of the foregoing for medical or veterinary purposes

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 20, 2025 NREP
PARTIAL INVALIDATION PROCESSED BY THE IB
Jan 3, 2021 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Nov 24, 2020 INPS
INVALIDATION PROCESSED
Nov 24, 2020 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Nov 12, 2020 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Mar 12, 2020 NA71
REGISTERED-SEC.71 ACCEPTED
Mar 12, 2020 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 12, 2020 APRE
TEAS SECTION 71 RECEIVED
Jan 29, 2020 ES71
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Mar 2, 2019 REM4
INTERNATIONAL REGISTRATION RENEWED
Jan 25, 2018 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Jun 2, 2017 INNP
GENERIC MADRID TRANSACTION SENT TO IB
Feb 18, 2017 XXSS
GENERIC MADRID TRANSACTION CREATED
Feb 18, 2017 XXCR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Nov 3, 2016 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Mar 3, 2016 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Mar 3, 2016 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 2, 2016 APRE
TEAS SECTION 71 & 15 RECEIVED
Feb 2, 2016 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Dec 14, 2013 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 5, 2013 FINO
CORRECTION UNDER SECTION 7 - PROCESSED
Jul 28, 2012 COC.
ASSIGNED TO PARALEGAL
Jul 28, 2012 PLGL
PETITION TO DIRECTOR DISMISSED
Mar 17, 2011 PC.D
ASSIGNED TO PETITION STAFF
Feb 18, 2011 APET
TEAS PETITION TO DIRECTOR RECEIVED
Jan 12, 2011 TPDR
NEW REPRESENTATIVE AT IB RECEIVED
Dec 16, 2010 NREP
FINAL DISPOSITION NOTICE SENT TO IB
Jun 17, 2010 FICS
FINAL DISPOSITION PROCESSED
Jun 17, 2010 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 2, 2010 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 2, 2010 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 15, 2009 NPUB
PUBLISHED FOR OPPOSITION
Dec 15, 2009 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 10, 2009 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 7, 2009 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 27, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 27, 2009 CRFA
ASSIGNED TO LIE
Oct 22, 2009 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 13, 2009 ERFR
EX PARTE APPEAL-INSTITUTED
Oct 13, 2009 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Oct 13, 2009 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Oct 13, 2009 EXAF
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jun 29, 2009 LIMN
LIMITATION OF GOODS RECEIVED FROM IB
Jun 19, 2009 LIMG
LIMITATION OF GOODS RECEIVED FROM IB
Jun 11, 2009 LIMG
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Apr 13, 2009 GNS1
SUBSEQUENT FINAL EMAILED
Apr 13, 2009 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Apr 13, 2009 CFRC
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 9, 2009 TEME
ATTORNEY REVIEW COMPLETED
Mar 9, 2009 ATRV
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 9, 2009 GNFN
FINAL REFUSAL E-MAILED
Mar 9, 2009 GNFR
FINAL REFUSAL WRITTEN
Mar 9, 2009 CNFR
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Feb 9, 2009 CREV
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 6, 2009 CRFA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 6, 2009 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 6, 2009 REAP
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 6, 2009 TROA
CORRECTION TRANSACTION RECEIVED FROM IB
Jan 22, 2009 CRCV
REFUSAL PROCESSED BY IB
Aug 22, 2008 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 7, 2008 RFCS
REFUSAL PROCESSED BY MPU
Aug 7, 2008 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 7, 2008 RFCR
NON-FINAL ACTION WRITTEN
Aug 6, 2008 CNRT
ASSIGNED TO EXAMINER
Jul 25, 2008 DOCK
NEW APPLICATION ENTERED
Jul 25, 2008 NWAP
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 24, 2008 REPR